Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis

Bone

Volumn 41, Issue 1, 2007, Pages 155-156

  Ferretti, Gianluigi ^a   Fabi, Alessandra ^a   Carlini, Paolo ^a   Papaldo, Paola ^a   Felici, Alessandra ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; MATRIX METALLOPROTEINASE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; LETTER; LOW DRUG DOSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 34249983137     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.04.177     Document Type: Letter

References (20)

1. Ferretti G., Fabi A., Carlini P., Papaldo P., Cordiali Fei P., Di Cosimo S., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69 1 (2005) 35-43
2. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 8 (2003) 2893-2897
3. Daubine F., Le Gall C., Gasser J., Green J., and Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99 4 (2007) 322-330
4. Coussens L.M., Tinkle C.L., Hanahan D., and Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103 (2000) 481-49037
5. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 10 (2000) 737-744
6. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 5 (2004) 623-633
7. Kerbel R.S., and Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 6 (Jun 2004) 423-436
8. Shaked Y., Emmenegger U., Francia G., Chen L., Lee C.R., Man S., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65 16 (Aug 15 2005) 7045-7051
9. Shaked Y., Emmenegger U., Man S., Cervi D., Bertolini F., Ben-David Y., et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106 9 (Nov 1 2005) 3058-3061
10. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
11. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 (2002) 1228-1236
12. 3H-etidronate in rat and mouse bones. Bone 19 (1996) 281-290
13. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
14. Thompson K., Rogers M.J., Coxon F.P., and Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69 5 (May 2006) 1624-1632
15. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12 20 Pt 2 (Oct 15 2006) 6222s-6230s
16. Gao L., Deng H., Zhao H., Hirbe A., Harding J., Ratner L., et al. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106 (2005) 4294-4302
17. van der Pluijm G., Que I., Sijmons B., Buijs J.T., Lowik C.W., Wetterwald A., et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65 (2005) 7682-7690
18. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl 4 (2004) 3-13
19. Woodward J.K., Coleman R.E., and Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 16 (2005) 11-19
20. Budman D.R., and Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70 (2006) 147-153